• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retina >Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome.
【24h】

Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome.

机译：光动力疗法和大剂量玻璃体内曲安奈德治疗渗出性年龄相关性黄斑变性：2年预后。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To evaluate the efficacy of photodynamic therapy (PDT) and high-dose intravitreal triamcinolone acetonide (TA) injection to treat choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) at the 2-year follow-up. METHODS: In this prospective, consecutive, comparative, nonrandomized, interventional case series, 30 eyes of 30 consecutive patients with subfoveal CNV associated with AMD were treated by PDT followed by intravitreal injection of 19.4 +/- 2.1 mg TA. Fifteen eyes were naive to treatment (group 1), and 15 had been treated previously by PDT alone (group 2). A group of 15 eyes of 15 patients treated by PDT alone served as controls. The number of Snellen lines gained or lost and PDT sessions were evaluated. RESULTS: Best-corrected visual acuity (BCVA) did not change significantly in group 1 from baseline (0.0 +/- 3.4 Snellen line; range, -5 to 9 Snellen lines; P 0.81); group 2 lost an average -0.6 +/- 2.5 line (range, -7 to 3 Snellen lines) (P = 0.41), and the control group lost an average of -2.2 +/- 3.4 lines (range, -8 to 2 Snellen lines) (P = 0.03, Wilcoxon signed rank test). The average number of PDT sessions during the 24-month follow-up was 1.9, 1.2, and 3.9 for group 1, group 2, and the control group, respectively. CONCLUSION: Two years after combined PDT/high-dose intravitreal TA to treat AMD-associated CNV, final BCVA was stable, and the need for retreatment was reduced compared with historical controls.
机译：目的：在两年的随访中，评估光动力疗法（PDT）和大剂量玻璃体内曲安奈德（TA）注射液治疗与年龄相关性黄斑变性（AMD）相关的脉络膜新生血管（CNV）的疗效。方法：在此前瞻性，连续，比较，非随机，干预性病例系列中，对30例连续的伴有黄斑中心凹的CNV患者与AMD相关的30只眼进行了PDT治疗，然后玻璃体内注射19.4 +/- 2.1 mg TA。 15眼未接受过治疗（第1组），而15眼先前仅接受过PDT治疗（第2组）。单独接受PDT治疗的15例患者中的15只眼作为对照组。 Snellen线路获得或丢失的数量以及PDT会话进行了评估。结果：第一组的最佳矫正视力（BCVA）与基线相比无明显变化（0.0 +/- 3.4 Snellen线;范围：-5到9 Snellen线; P 0.81）;第2组平均损失-0.6 +/- 2.5行（范围为-7到3个Snellen行）（P = 0.41），而对照组平均损失-2.2 +/- 3.4行（范围为-8到2） Snellen线）（P = 0.03，Wilcoxon符号秩检验）。第1组，第2组和对照组在24个月随访期间的平均PDT会话数分别为1.9、1.2和3.9。结论：PDT /大剂量玻璃体内TA联合治疗AMD相关CNV两年后，最终BCVA稳定，与历史对照相比，减少了再次治疗的需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号